Listen Here:
Click or simply search “Sigma Nutrition” on your podcast platform of choice.
Or listen directly on the Sigma website here.
Introduction
GLP-1 receptor agonists have emerged as a groundbreaking tool in obesity treatment. In this episode, Dr. Spencer Nadolsky (an obesity specialist) explains how these medications are now yielding unprecedented weight loss outcomes in people with obesity.
The discussion centers on GLP-1 agonist drugs like semaglutide and tirzepatide: how they work, how much weight loss they can produce, and why they represent a paradigm shift in obesity management.
Importantly, the conversation addresses practical aspects of using these drugs, including managing their side effects and optimizing patients’ diet and lifestyle while on therapy.
This topic is of great significance to nutrition science, clinical practice, and public health. Obesity is a chronic, relapsing condition that has proven difficult to treat with lifestyle changes alone. The advent of GLP-1 agonists offers new hope by inducing weight loss levels previously seen only with surgical interventions.
Understanding these medications is crucial for healthcare professionals: it enables evidence-based prescribing, proper patient counseling on diet and side effects, and integration of medication with lifestyle interventions.
Discussing safety and long-term use is vital, as millions more patients might use these drugs in coming years. From a public health perspective, GLP-1 agonists prompt debates about access and cost, given their high price and life-changing potential.
Related resources
- Join the Sigma newsletter for free
- Subscribe to Sigma Nutrition Premium
- Enroll in the next cohort of our Applied Nutrition Literacy course
- Vineyard – Dr. Nadolsky’s Virtual Clinic (US)
- Instagram:
- Related episodes:
- [03:25]Conversation with Dr. Spencer Nadolsky begins
- [05:24]Mechanism and types of GLP-1 medications
- [07:55]Efficacy and weight loss results
- [16:53]Common side effects and management
- [22:57]Muscle loss concerns and clinical insights
- [28:09]Addressing nutritional concerns with GLP-1 medications
- [29:38]Exploring potential benefits beyond weight loss
- [33:48]Marketing and misconceptions around GLP-1
- [36:59]Public health and accessibility issues
- [43:25]Future research
- [46:16]Key ideas segment (Premium-only)
Guest Information
Click through to your app of choice to listen and subscribe:
Dr. Spencer Nadolsky is a board-certified obesity and lipid specialist physician whose clinical work focuses on evidence-based management of metabolic diseases through lifestyle and medical interventions. With a background in family medicine and exercise physiology, he emphasizes practical, data-driven strategies for improving cardiometabolic health and addressing conditions such as obesity, dyslipidemia, and insulin resistance. He also serves as the founder and director of Vineyard, a physician-led virtual care platform dedicated to helping patients achieve sustainable weight and metabolic outcomes through continuous, personalized support grounded in sound clinical evidence.
Danny Lennon has a master’s degree (MSc.) in Nutritional Sciences from University College Cork, and he is the founder of Sigma Nutrition.
Danny is currently a member of the Advisory Board of the Sports Nutrition Association, the global regulatory body responsible for the standardisation of best practice in the sports nutrition profession.
Introduction to this Episode
GLP-1 receptor agonists have emerged as a groundbreaking tool in obesity treatment. In this episode, Dr. Spencer Nadolsky (an obesity specialist) explains how these medications are now yielding unprecedented weight loss outcomes in people with obesity.
The discussion centers on GLP-1 agonist drugs like semaglutide and tirzepatide: how they work, how much weight loss they can produce, and why they represent a paradigm shift in obesity management.
Importantly, the conversation addresses practical aspects of using these drugs, including managing their side effects and optimizing patientsʼ diet and lifestyle while on therapy.
This topic is of great significance to nutrition science, clinical practice, and public health. Obesity is a chronic, relapsing condition that has proven difficult to treat with lifestyle changes alone. The advent of GLP-1 agonists offers new hope by inducing weight loss levels previously seen only with surgical interventions.
Understanding these medications is crucial for healthcare professionals: it enables evidence-based prescribing, proper patient counseling on diet and side effects, and integration of medication with lifestyle interventions.
Discussing safety and long-term use is vital, as millions more patients might use these drugs in coming years. From a public health perspective, GLP-1 agonists prompt debates about access and cost, given their high price and life-changing potential.
Useful Terminology for this Episode
- GLP-1 (Glucagon-Like Peptide-1): A hormone released from the gut in response to eating. GLP-1 increases insulin release, slows gastric emptying, and reduces appetite. It normally breaks down in minutes, so analogs are needed to have lasting effects.
- GLP-1 Receptor Agonist (GLP-1 RA): A class of medications that mimic the GLP-1 hormone by activating its receptor. These drugs (e.g. liraglutide, semaglutide) prolong GLP-1ʼs action, leading to lower blood sugar and suppressed appetite. They were first used for diabetes and later approved for obesity due to their weight-loss effects.
- Incretin Effect: The phenomenon where orally ingested glucose triggers a greater insulin response than intravenous glucose. This occurs because gut hormones (incretins like GLP-1 and GIP) are released during eating and amplify insulin secretion. The incretin effect led to the discovery of hormones that could be harnessed as drugs for diabetes/obesity.
- Gastroparesis: A medical term for delayed gastric emptying (food moving slowly from the stomach to small intestine). Severe gastroparesis can cause nausea, vomiting, and “stomach paralysis” symptoms. GLP-1 agonists intentionally slow gastric emptying to promote satiety, but persistent gastroparesis as a side effect is very rare and not clearly caused by these drugs in humans.
- GIP (Glucose-Dependent Insulinotropic Polypeptide): An incretin hormone from the gut that, like GLP-1, stimulates insulin release after meals. Tirzepatide is a “dual agonist” that activates both GLP-1 and GIP receptors (hence nicknamed a twincretin), aiming to enhance weight loss and metabolic benefits by leveraging two hormones.
- Medullary Thyroid Carcinoma (MTC): A rare thyroid gland cancer arising from C-cells. Itʼs noted in this context because high doses of GLP-1 agonists caused C-cell tumors in rodent studies. Although no increased risk has been seen in humans, GLP-1 drugs carry a warning against use in patients with a family history of MTC as a precaution.
